1783 results about "Cell activity" patented technology

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides appropriately functionalized 5,6-fused bicyclics which inhibit, regulate and / or modulate kinase receptor, particularly c-Met, KDR, and flt-3, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

The invention, in some aspects relates to compositions and methods for altering cell activity and function and the use of light-activated ion pumps (LAIPs).

The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.

Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (RORγ) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and / or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of RORγ results in stimulation of TH-17 cell function and / or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).

A cell potential measurement apparatus, which uses a planar electrode enabling a multi-point simultaneous measurement of potential change arising from cell activities, is provided which can conduct measurements accurately and efficiently as well as can improve convenience of arranging measurement results. According to the configuration of the cell potential measurement apparatus of this invention, it includes an integrated cell holding instrument 1, which includes a planar electrode provided with a plurality of microelectrodes arranged in a matrix form on the surface of a substrate, a cell holding part for placing cells thereon, drawer patterns from the microelectrodes, and electric contact points for outside connections; an optical observation means 20 for optical observations of cells; a stimulation signal supply means 30 to be connected to the cell holding instrument for providing electric stimulation to the cells; and a signal processing means 30 to be connected to the cell holding instrument for processing an output signal arising from electric physiological activities of the cells. It is preferable that a cell culturing means 40 is also provided for maintaining a culture atmosphere of the cells placed on the integrated cell holding instrument.

This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.

The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and / or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR1R1a, or O—R1, wherein X is H, halo, C1-C6 alkyl, NO2, mono-, di-, or tri-halo substituted methyl, NR13R,14. C(O)O—C1-C6 alkyl, or N(R13)—C(O)—C1-C6 alkyl; Y is H, halo, OH, C1-C6 alkyl, C0-C6alkyl-NR,15R16, NR15R,6, C1-C6 alkoxy, —N(R13)—(CH2)n-NR15R16, —C(O)O—C1-C6 alkyl, —O—(CH2)n—NR15R16, —C(O)—C1-C6 alkyl, —C0-C6-alkyl-R21, —O—R21, —C(O)—R21, —O—(CH2)n—R21, —C(O)—NR13R14, —C(O)—N(R13)-aryl, —C(O)—N(R13)(CH2)n—NR15R16, —C(O)—N(R13)—(CH2)n-aryl —C(O)—N(R13)—(CH2)n-heterocyclyl; or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S. Z is H, NR2R3, —S—R2a, or —O—R2a

The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

The invention provides a serum-free cell culture fluid suitable for enriching and culturing tumour stem cells. DMEM / f12 serves as the basic culture fluid of the serum-free cell culture fluid and transferrin, insulin and other substances are also added as the components of the serum-free cell culture fluid. The serum-free cell culture fluid provided by the invention can efficiently enrich tumour stem cells from malignant tumour cell strains and tumour tissues. In addition, the serum-free cell culture fluid can promote stable growth of the tumour stem cells and maintain fine cell activity and physiological properties of the tumour stem cells, thus being very suitable for research fields related to tumour cells and tumour stem cells.

Extracts from plant material, or semi-purified / purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus, the use of the extracts to slow down, inhibit or prevent abnormal cell migration in an animal is also provided. Methods of selecting and preparing the plant extracts and methods of screening the extracts to determine their ability to modulate one or more cellular activity are described. The purification or semi-purification of one or more molecules from the described extracts is also contemplated as well as the use of these molecules, alone or in combination with an extract, to slow down, inhibit or prevent abnormal cell migration in an animal.

The invention relates to a novel bufadienolides compound and a preparation method and application thereof, and provides a bufadienolides compound having a general formula (I) or pharmaceutical acceptable salts as well as bufadienolides extract or medication composition containing the compound. The compound and the extract have effect for inhibiting tumour cell activity and application to preparation of anti-tumour drugs. The invention also provides the preparation method applicable for industrial production of the compound and the extract.

The invention provides a method for storing mesenchymal stem cells and a method for culturing mesenchymal stem cells. The storing method comprises the following steps of: cutting the umbilical cord into blocks, and putting the blocks into a mixed solution of freezing storage solution and base solution in a volume rate of 1:3 for pretreatment; putting the blocks in the mixed solution of the freezing storage solution and the base solution in a volume rate of 1:1 for treatment at the temperature of 0 DEG C; putting the blocks in the freezing storage solution for treatment at the temperature of 0DEG C; and freeze-storing the blocks in liquid nitrogen. The culturing method is that the stored umbilical cord blocks are used for culture. After babies are delivered, the expensive cell culturing operation of the umbilical cords is not required immediately, the umbilical cords can be directly frozen at the deep low temperature, and the cell activity is not affected. One freezing storage tube can be picked up at any time, the umbilical cords are recovered and successfully cultured and amplified to obtain MSCs, so that the culture operation is not required to be made for each portion of umbilical cord, and the operating cost of the umbilical cord MSCs storage warehouse is greatly lowered.

The invention discloses a cryoprotective agent of peripheral blood mononuclear cells. The cryoprotective agent is prepared from the following ingredients in parts by weight: 43-53 parts of a culture medium, 30-40 parts of auto-plasma, 12-17 parts of dimethyl sulfoxide, 5-7% of human serum albumin, and the balance being 0.17-0.23mol / L trehalose. The invention discloses a preservation method of the cryoprotective agent. The preservation method comprises the steps of collecting fresh anticoagulation blood, preparing peripheral mononuclear cells into cell suspension by using human serum albumin, adding the cryoprotective agent with the same volume as that of the cell suspension, mixing uniformly, preserving for 10-20h at below 90-below-70-below DEG C, and preserving in liquid nitrogen. According to the cryoprotective agent and the preservation method thereof, a cryopreserved cell has the high motility rate and the strong cell activity and can shorten the Cytokine Induced Killer (CIT) cell induced amplification period.

A device for positioning at least one cell in at least one addressable position, the device comprising a substrate (12) formed with at least one addressable pore (14) and at least one channel (16) embedded in the substrate and being held in fluid communication with the at least one pore. The at least one pore and the at least one channel are designed and constructed such that an under-pressure formed in the at least one channel results in vacuum adherence of the at least one cell onto the at least one pore, such that a single cell is vacuum adhered onto a single pore. In one embodiment, the substrate is a non-conductive substrate and is further formed with one or more electrode structures (22), where each of the electrode structures is positioned in one of the pores. In an additional embodiment the device is designed to be locatable on an organ, such as the brain.

The invention discloses a mesenchymal stem cell self-preserving liquid which is prepared from the following raw materials according to volume ratios: 1-6% of self platelet lysate, 95-97% of solution medium and 0-1% of vitamin C injection, wherein the solution medium is a mixed sugar electrolyte injection or physiological saline injection. The mesenchymal stem cell self-preserving liquid has the advantages that: growth factors contained in the mesenchymal stem cell self-preserving liquid can maintain the activity state of cells, the vitamin C can maintain the activity of various peroxidases, at the same time, the mixed sugar electrolyte injection is especially suitable for cell preservation, and osmotic pressure is also favorable for nutrient absorption of the cells so as to carry out metabolism; the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 8 hours is still larger than 90%, the cell activity change is not larger than 7%, and the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 12 hours is still maintained at 85%; and by using the mesenchymal stem cell self-preserving liquid, the requirements for human intravenous back-transfusion safety can be met, and the cell preserving problem of long-time transport is solved, thus more patients have opportunity to undergo mesenchymal stem cell treatment.

The present subject matter relates to red emitting mitochondria-targeted aggregation induced emission (AIE) probes as an indicator for membrane potential and mouse sperm activity. The present subjectmatter relates to AIE-active fluorescent probes for reactive oxygen species (ROS) detection and related biological applications, such as inflammation imaging and glucose assay, as well as the preparation and application of red fluorescent AIEgens.

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

The invention discloses a preparation method of a CAR-T cell for treating AIDS-related lymphoma. A CD8+ T cell is used to produce the CAR-T cell, and the CD8-T cell derives from a cord blood T cell. The method includes the following steps: preparing cord blood mononuclear cells from cord blood, removing tumors and other cells by using a human T cell purification kit to obtain T cells, and carryingout separation by using magnetic beads to obtain the CD8+ T cell; activating the CD8+ T cell by using an appropriate medium and appropriate stimulation conditions; transferring CAR to the CD8+ T cellby using lentivirus to prepare the CAR-T cell; and amplifying the CAR-T cell in vitro by using cytokines and activating stimulators to achieve the desired effective dose. The invention also relates to the CAR-T cell prepared by the method, and an application thereof. The CAR-T cell prepared in the invention has a good cell activity and a high proliferation speed, and reduces the attack risk of GVHD; and only the CD8+T cell of the umbilical blood T cells of AIDS patients is used to prepare the CAR-T cell for, so the risk of input CAR-T infected with in-vivo HIV is reduced.

The invention discloses a dendrobium officinale stem cell and an isolated culture method thereof. The method comprises the following steps: culturing plant root tissue containing a quiescent centre, performing subcultring and scale-up culture on quiescent centre stem cell, and then preparing stem cell dry powder or extracting solution according to requirements. The dendrobium officinale stem cell overcomes the problem that dendrobium officinale in vitro material is easy to brown, the cell of a stem cell line is not differentiated, the cell increment is large in a nutritional condition, the culture time is short, and the cell activity is high. The dendrobium officinale stem cell and the method have the advantages that the technical process is easy to operate, the quantity of technological processes is less, the output is high, and the dendrobium officinale stem cell obtained is anti-aging and oxidation resistant, promotes hair growth and high baldness-resistant activity, and can be manufactured into functional health care products and cosmetics for preventing and curing various senescence and baldness and relevant Chinese drugs for preventing senescence and baldness.

The invention discloses a method for preparing essence of stem cell factor with an anti-aging effect. The method comprises the steps that step 1, human umbilical cord mesenchyma stem cells are prepared and cultured, stem cell culture supernatant is collected, concentrate is obtained after concentration is conducted, and the concentrate is further frozen and dried to prepare the lyophilized powderof the stem cell factor; step 2, the components of, by volume, 0.1-1% of hyaluronic acid, 1-10% of glycerol, 0.1-1% of collagen protein, 0.1-1% of tea polyphenols and the balance water are mixed to obtain solvent; step 3, the solvent is added into the lyophilized powder of the stem cell factor to be thoroughly dissolved to obtain the essence of the stem cell factor. The prepared essence of the stem cell factor comprises multiple kinds of cell active factor components such as epidermal growth factor, vascular endothelial growth factor, hepatocyte growth factor, nerve growth factor and the like,the essence can nourish skin, promote skin repairing and regenerating, resist wrinkles, remove colored patches and the like, and the essence has better application value in the field of medical beauty.

A method of making a three-dimensional biocompatible scaffold capable of supporting cell activities such as growth and differentiation, the method includes providing a supporting grid that forms an open network and provides mechanical support of a second biocompatible material. The second biocompatible material has interconnected cavities that allow nutrients, metabolites and soluble factors to diffuse throughout the scaffold. The scaffold design can be understood as a hierarchically organised structure. At the micron to submicron length scale a top / down manufacturing approach is used to make a structure that will constitute the frame into which a bottom / up processing approach is applied to form an open porous scaffold with specific nano sized features. The advantage of this hierarchically organised design is that benefits can be drawn independently from both the micron and the nano sized structures, promoting specific cell activities and providing sufficient mechanical compliance.

The invention provides a hepatoxic substance sieving and evaluating method based on cell states labeled by fluorescence, which is a sieving and evaluating method combining a hardware / software system. The images are acquired by a fluorescence inverted microscope and a computer in real time, the biological information is processed and visualized, the liner dynamic range width of the living cell is measured by combining FDA dyeing, and then the relevant parameters for evaluating the hepatoxic substances are provided. The method is quick, sensitive and economical, and is used for quickly detecting the influence of the sieved sample on cell quantity, forms, migration, apoptasis and the like under the condition of maintaining cell structure and function integrity, accurately carrying out quantitative analysis on the activity of the cell labeled by the fluorescence specialty and detecting the activity change of the cell under the function of the hepatoxic substances. The method has reasonable design. The provided sieving and evaluating system has complete structure, and can be used for sieving and evaluating the hepatoxic substances.

The invention discloses an anti-allergic skin-whitening mask solution and a preparation method thereof. The anti-allergic skin-whitening mask solution is prepared from the following components in percentage by weight: 0.1-2 percent of O / W-type emulsifier, 0.1-2 percent of co-emulsifier, 0.1-1 percent of antioxidant, 3-8 percent of emollient, 0.01-0.2 percent of ethylene diamine tetraacetic acid disodium (EDTA-2Na), 0.01-5 percent of desensitizer, 1-8 percent of first moisturizer, 0.01-0.5 percent of thickener, 0.01-0.5 percent of second moisturizer, 0.01-0.5 percent of pH modifier, 0.01-0.5 percent of preservative, 1-6 percent of glucan, 0.01-0.5 percent of rose essential oil, 0.01-0.3 percent of agave leaf extract, 0.5-2 percent of rice bran yeast and the balance of deionized water. The mask solution has the advantages that the preparation method is simple; by virtue of an oil-in-water emulsification system, functional matters in the mask solution are more easily absorbed and permeate into the skin, high activity is kept, the cell activity is comprehensively improved, the skin reviving process is accelerated, the skin is kept wetted and translucent, the health and the elasticity of the skin are restored, and the soothing effect and the repairing effect are achieved.

This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, granzyme B activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced granzyme B activation in target cells is achieved through detection of the specific cleavage of fluorogenic granzyme B substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard 51Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.